Medical University Reaviz

Samara 443011

0 studies enrolling now · 14 studies all time

What they study most

Chemotherapy-induced Neutropenia, Chronic Pancreatitis, Colitis, Ulcerative, Crohn's Disease, Hepatitis Delta Virus, Ulcerative Colitis

Studies at this site

• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 — Completed
• A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease — Stopped early
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Completed
• Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a — Completed
• A Dose Ranging Study Evaluating Efficacy and Safety of NI-03 — Completed
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis — Completed
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) — Stopped early